Scarica l'app Stockscreener
34.18
0.90%
-0.31
Dopo l'orario di chiusura:
34.18
Arrivent Biopharma Inc Borsa (AVBP) Ultime notizie
ArriVent’s Emerging CDH17-Targeted ADC Pipeline Supports Maintained Buy Rating and $45 Price Target - TipRanks
ArriVent BioPharma, Inc. Financial Disclosures & SEC Filings - TradingView
Price-Driven Insight from (AVBP) for Rule-Based Strategy - Stock Traders Daily
Number of shareholders of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Number of shareholders of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Enterprise value to revenue forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to book forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
Price to earnings forward of ArriVent BioPharma, Inc. – BOATS:AVBP - TradingView
Price to sales forward of ArriVent BioPharma, Inc. – NASDAQ:AVBP - TradingView
AVBP 260717 5.00P (AVBP260717P5000) Stock Options Chain | Quotes & News - Moomoo
ArriVent BioPharma, Inc. Actuals & Estimates (NASDAQ:AVBP) - TradingView
AVBP Forecast — Price Target — Prediction for 2027 - TradingView
Arrivent Biopharma Inc (AVBP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Form 4 Arrivent Biopharma Inc For: 22 June By Investing.com - Investing.com India
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options - Stock Titan
ArriVent BioPharma (AVBP) director receives grant of 13,562 stock options at $31.74 - Stock Titan
ArriVent BioPharma Stockholders Back Board and Auditor Slate - TipRanks
ArriVent BioPharma (NASDAQ: AVBP) 2026 meeting backs board, auditor - Stock Titan
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD - Investing.com UK
Arrivent Biopharma Inc stock hits 52-week high at 33.65 USD By Investing.com - Investing.com South Africa
Truist Financial Initiates ArriVent BioPharma(AVBP.US) With Buy Rating, Announces Target Price $31.74 - Moomoo
(AVBP) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arrivent Biopharma Inc (AVBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arrivent Biopharma Inc (AVBP) Institutional Confidence - TradingKey
Arrivent Biopharma Inc (AVBP) Valuation: PE, PB & Fair Value Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Arrivent Biopharma Inc (AVBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVBP: Directors were elected through 2029 and the auditor's appointment was ratified with strong support - TradingView
Arrivent Biopharma Inc (AVBP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Arrivent Biopharma Inc (AVBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arrivent Biopharma Inc (AVBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ArriVent BioPharma (AVBP) Stock Valuation After Growing Expectations For EGFR Firmonertinib Trials - Sahm
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
AVBP Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues R&D InvestmentsTangible Book Value - newsline.com
AVBP Q1 2026 Earnings: EPS Miss Slightly Wider Than Forecast as Pre-Revenue Biotech Advances PipelineFinancial Data - dars.gov.et
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
(AVBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
AVBP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analysts Offer Insights on Healthcare Companies: Vanda (VNDA), ArriVent BioPharma, Inc. (AVBP) and Medtronic (MDT) - The Globe and Mail
ArriVent’s MRG007 Phase I Trial Progress Adds Long-Term Option Value for AVBP Investors - TipRanks
Guggenheim Remains a Buy on ArriVent BioPharma, Inc. (AVBP) - The Globe and Mail
Cantor Fitzgerald reiterates Overweight on ArriVent BioPharma stock By Investing.com - Investing.com Canada
Why Is ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Down Today? - Meyka
Analyst Reiterates Buy on ArriVent, Maintains $42 Price Target on Firlotinib Confidence After Sunvozertinib Data - TipRanks
Oppenheimer Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $50 - Moomoo
AVBP Q1 2026 Earnings: EPS Misses Estimates as Stock Surges 11% on Pipeline OptimismShare Dilution Risk - The Legal Advocate
ArriVent BioPharma Price Target Raised to $45.00/Share From $43.00 by Truist Securities - Moomoo
ArriVent Biopharma assumed with a Buy at Truist - TipRanks
Truist Financial Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
(AVBP) Risk Channels and Responsive Allocation - Stock Traders Daily
ArriVent BioPharma (AVBP) Eases 1.68%; Support at $26.1 in Focus After Sector HeadwindsResistance Breakout Stocks - The Legal Advocate
ArriVent BioPharma (AVBP) Slips 1.68% Amid Sector Rotation – Key Support at $26.1 HoldsUndervalued Stocks - newsline.com
AVBPArriVent BioPharma Inc Stock Price and Quote - Finviz
ArriVent BioPharma Shares Edge Lower Amid Sector CautionKAMA Signal - Newser
Cantor Fitzgerald reiterates Overweight rating on ArriVent stock By Investing.com - Investing.com Canada
Does Indivior Pharmaceuticals Inc. (INDV) Have the Potential to Rally 32.48% as Wall Street Analysts Expect? - Yahoo Finance
B. Riley Securities Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
(AVBP) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
1.18%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):